Oncimmune® (USA) LLC Experiences Increased Interest in EarlyCDT®-Lung as Doctors Place New Emphasis on Lung Cancer Screening with CT, in Response to Landmark NLST Study

Share Article

Research released by the National Lung Cancer Screening Trials (NLST) found that early detection, enabled by low-dose CT scans, resulted in a 20% reduction in lung cancer mortality in a high risk patient population. Doctors and researchers at Oncimmune® are already reporting that these NLST findings, announced earlier this year, are having a noticeable impact on the way physicianses diagnose and monitor lung cancer.

We are encouraged to see the medical community focus on various methodologies to discover lung cancer at earlier stages.

Oncimmune® (USA) LLC, creator of EarlyCDT®-Lung, a simple blood test that aids physicians in the risk assessment and early detection of lung cancer, is experiencing increased interest in EarlyCDT-Lung. The increased interest comes, in part, in the wake of the findings from the National Lung Cancer Screening Trials (NLST) study which found that early detection, enabled by low-dose CT scans, resulted in a 20 percent reduction in lung cancer mortality in a high risk patient population.

Oncimmune’s EarlyCDT-Lung test uses a panel of tumor antigens to detect the presence of immuno-biomarkers produced in the form of autoantibodies by the patient’s immune system when lung cancer is present. Elevation of any one of the panel of immuno-biomarkers (autoantibodies) above a predetermined cut-off value suggests that a tumor might be present and the lung nodule is malignant. Previous studies have shown that immuno-biomarkers can be detected up to five years before tumors can be seen in routine diagnostic imaging procedures.

The study from a National Lung Cancer Screening Trials study (NLST), first published in the New England Journal of Medicine (NEJM) in July of this year, found that participants who received low-dose helical CT scans had a 20 percent reduction in dying from lung cancer than participants who received standard chest X-rays. To complete the research, NLST enrolled 53,454 current or former heavy smokers from 33 sites and coordinating centers across the United States.

This landmark study is already proving to have a profound impact on the way medical professionals approach lung cancer diagnosis. In an effort to detect early stage lung cancer, many hospitals are now offering lung cancer screening programs, which typically include low dose CT scans in high risk patients. In addition, many physicians are recommending that high risk patients also take the EarlyCDT-Lung blood test. EarlyCDT-Lung is designed to aid doctors who are monitoring high risk patients for signs of lung cancer, including those with indeterminate pulmonary nodules discovered by CT. This critical information can aid in the early diagnosis of the disease.

“We are encouraged to see the medical community focus on various methodologies to discover lung cancer at earlier stages,” said Dan Calvo, President and CEO of Oncimmune. “Finding lung cancer early can positively impact the outcome for patients”

The doctors and researchers behind EarlyCDT-Lung are committed to promoting public awareness around the importance of early lung cancer detection efforts. They are working with physicians and healthcare administrators nationwide to make EarlyCDT-Lung available to high risk patients. Watch for more exciting announcement from the Oncimmune team as they continue their work in the fight against lung cancer.

About Oncimmune LLC

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. The company is committed to advancing early cancer detection through proprietary immuno-biomarker technologies based on biological technology identified by John Robertson, M.D., Professor of Surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Professor Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90% of solid-tumor cancers, which make up 70% of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. All testing is performed exclusively at Oncimmune’s CLIA (Clinical Laboratory Improvement Act) regulated laboratory located in the metro Kansas City area. Oncimmune (USA) LLC is a wholly owned subsidiary of Oncimmune LTD. Oncimmune LTD owns a portfolio of patents, including Patent Nos. 7,402,403 and 7,205,117, with five others currently filed and under review. For more information about Oncimmune, visit: http://www.hellohaveyouheard.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Stanley
Visit website

Media

Finding lung cancer at its earliest stages